GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Talphera Inc.
Talphera's stock reflects its focus on developing drugs for niche markets. Its price trajectory depends on clinical trial results and the company's ability to commercialize its products in narrow therapeutic areas.
Share prices of companies in the market segment - Pharma virus
Talphera is a pharmaceutical company focused on developing treatments for viral and bacterial infections. We've categorized it under "Pharma: Viruses," and the chart below shows how investors value companies working to protect against infectious threats.
Broad Market Index - GURU.Markets
Talphera is a pharmaceutical company specializing in developing drugs to treat viral and other diseases. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock to assess the outlook for this industry.
Change in the price of a company, segment, and market as a whole per day
TLPH - Daily change in the company's share price Talphera Inc.
Talphera, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news regarding the development and commercialization of its antiviral drugs.
Daily change in the price of a set of shares in a market segment - Pharma virus
Talphera, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TLPH's performance, which is dependent on clinical trial results, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Talphera is a pharmaceutical company specializing in the treatment of viral infections. Its shares are driven by news about new drug developments. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Talphera Inc.
Talphera, Inc.'s year-over-year performance is a story of developing a new approach to treating viral and oncological diseases. Its 12-month market capitalization is entirely dependent on clinical trial data. The success of its unique platform could offer new, more effective therapies for patients with serious illnesses.
Annual dynamics of market capitalization of the market segment - Pharma virus
Talphera, Inc. is a biopharmaceutical company. Its success depends on the commercialization of its approved drugs and the results of R&D. The chart shows how its focus on niche diseases and the competitive environment influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Talphera (formerly AcelRx) is a pharmaceutical company whose performance depends on the commercial success of its acute pain medications. Market benchmarking shows whether the company is growing sales and gaining market share. Successful commercialization is key to outperforming the broader index, while weak sales lead to underperformance.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Talphera Inc.
Talphera is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends entirely on progress in its scientific developments and clinical programs. News of trial results or funding raises are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Pharma virus
Talphera is a biopharmaceutical company specializing in the development of drugs to treat viral and bacterial infections. Their success depends on clinical trial results and regulatory approval. The chart below shows the overall dynamics in the pharmaceutical sector, where infection control remains a priority.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pharmaceutical stocks, especially after approvals, can move on commercial launch news. The chart below shows general trends. Is Talphera, Inc. living up to its story, where sales growth trumps overall market sentiment?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Talphera Inc.
Talphera, a pharmaceutical company focused on developing and commercializing products for critical care, is news-sensitive. Weekly stock performance reflects decisions by regulators, such as the FDA, and progress in commercializing its products intended for use in critical situations.
Weekly dynamics of market capitalization of the market segment - Pharma virus
Talphera operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether TLPH is moving with the industry or whether its drug development successes are creating their own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Talphera, Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on FDA decisions. The chart below clearly demonstrates how TLPH shares can live their own life, separate from the broader market, moving on their own news.
Market capitalization of the company, segment and market as a whole
TLPH - Market capitalization of the company Talphera Inc.
Talphera's chart is a story about finding new uses for existing drugs. The company focuses on developing new compounds to treat viral and other diseases. Its market cap dynamics reflect how investors view this lower-risk strategy and its progress in clinical trials.
TLPH - Share of the company's market capitalization Talphera Inc. within the market segment - Pharma virus
Talphera, Inc. is a biopharmaceutical company developing drugs for rare diseases. Its share in the sector will be based on the potential of its pipeline of candidates. The chart will show how the market assesses its chances of commercializing drugs for patients with unmet medical needs.
Market capitalization of the market segment - Pharma virus
Talphera, Inc. develops drugs to treat viral and bacterial infections. The chart below shows the pharmaceutical sector's market capitalization. This is a valuation of a vital industry at the forefront of the fight against infectious diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Talphera is a pharmaceutical company specializing in the development of drugs for the treatment of viral diseases and oncology. Its market capitalization reflects the potential of its scientific developments. The chart below shows the economic weight of companies in early-stage research.
Book value capitalization of the company, segment and market as a whole
TLPH - Book value capitalization of the company Talphera Inc.
Talphera is based on drug delivery technology. The company's book value, formerly known as AcelRx, reflects its patents for sublingual tablets and delivery devices that enable rapid delivery of potent analgesics. The chart below shows how the company manages its unique technological and financial capital.
TLPH - Share of the company's book capitalization Talphera Inc. within the market segment - Pharma virus
Talphera, Inc., a pharmaceutical company, is focused on R&D. Its laboratories are its primary physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - Pharma virus
Talphera is a pharmaceutical company developing drugs to treat viral and bacterial infections. Its assets currently consist of intellectual property. The chart will show how "light" its balance sheet is, with all its value concentrated in future drugs.
Book value of all companies included in the broad market index - GURU.Markets
Talphera's assets are in nasal drug delivery technology. The company's book value reflects its platform rights and capital for developing nasal sprays for the treatment of migraines and other conditions. This provides the foundation for creating drugs that act faster and more conveniently than tablets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Talphera Inc.
Talphera is a pharmaceutical company developing drugs to treat viral and other diseases. Its book value is cash. Its market capitalization is an estimate of its scientific developments and the likelihood of its drugs being successful in clinical trials and subsequent commercialization.
Market to book capitalization ratio in a market segment - Pharma virus
Talphera is a pharmaceutical company developing drugs to treat viral and other diseases. Its value depends on the success of its clinical programs. The chart shows how market expectations for its development pipeline compare to its tangible assets.
Market to book capitalization ratio for the market as a whole
Talphera is a pharmaceutical company developing drugs to treat bleeding disorders. Its value is determined by the potential of its products. The chart demonstrates how market valuation reflects investors' faith in science and future cash flows, rather than current tangible assets.
Debts of the company, segment and market as a whole
TLPH - Company debts Talphera Inc.
Talphera, a pharmaceutical company, uses debt to finance commercialization and development. This chart shows how the company raises capital to market its already approved products and conduct clinical trials to expand their use or introduce new formulations.
Market segment debts - Pharma virus
Talphera is a pharmaceutical company focused on developing treatments for patients with critical illnesses. Its financial health, like that of other development-stage companies, depends entirely on the success of clinical trials and its ability to raise capital. This chart shows its cash reserves available for continuing R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Talphera Inc.
Talphera, Inc. (formerly AcelRx Pharmaceuticals) specializes in acute pain medications. This chart shows how the company finances the commercialization of its products. For a pharmaceutical company with an approved drug, debt can be a tool for building a sales and marketing system, but it creates pressure to achieve profitability.
Market segment debt to market segment book capitalization - Pharma virus
Talphera, Inc. is a pharmaceutical company specializing in drugs for the treatment of viral and other diseases. This pharmaceutical industry chart reflects how companies fund research and the launch of new products. It provides context for assessing the company's financial strategy and risks on its path to commercialization.
Debt to book value of all companies in the market
Talphera, Inc. develops drugs to treat viral and bacterial infections. The pharmaceutical sector requires significant investment in research. A chart showing the debt-to-book value ratio of the overall market is important for assessing the investment climate, which determines Talphera's ability to fund its clinical programs and bring products to market.
P/E of the company, segment and market as a whole
P/E - Talphera Inc.
Talphera is a pharmaceutical company specializing in the development of drugs for the treatment of viral and other diseases. This chart reflects investor assessments of its development pipeline. The performance of this indicator depends on clinical trial results and regulatory decisions, which may either approve its drugs, paving the way for revenue, or reject them.
P/E of the market segment - Pharma virus
Talphera, Inc. is a biotech company. This chart shows the average P/E ratio for the biotech sector. Comparing a company's P/E to this benchmark allows one to understand how highly the market values its development pipeline compared to the average prospects of other biotech companies.
P/E of the market as a whole
Talphera is a pharmaceutical company specializing in developing drugs for rare diseases. Its strategy is to identify and develop promising candidates for niche markets. This chart shows the mood in the biotech sector. The company's valuation depends on the success of its clinical programs and its ability to obtain regulatory approval for its orphan drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Talphera Inc.
Talphera is a pharmaceutical company focused on developing drugs for the treatment of viral diseases and oncology. The chart reflects investor expectations for future revenue, which depend on the success of clinical trials and regulatory approvals for its drug candidates.
%20P%2FE%20Talphera%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Talphera-Inc.&v=1772540176066 "Chart of the company's future (projected) P/E Talphera Inc.")
Future (projected) P/E of the market segment - Pharma virus
Talphera is a pharmaceutical company developing drugs to treat viral and other diseases. This chart provides investors with context, showing average profitability expectations in the sector and allowing them to assess how the market perceives its scientific developments and potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-virus&v=1772540176090 "Future (projected) P/E graph of the market segment - Pharma virus")
Future (projected) P/E of the market as a whole
Talphera is a biopharmaceutical company specializing in the development of drugs to treat viral and bacterial infections. Its valuation is based on expectations of success in clinical trials. Amidst general market forecasts, Talphera operates at its own pace, driven by regulatory announcements and laboratory data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772540176117 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Talphera Inc.
Talphera, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of serious diseases. Its financial performance depends on the success of clinical trials and the subsequent approval and sales of its drugs. This chart shows the company's financial trajectory as it strives to bring new therapeutic solutions to market.
Profit of companies in the market segment - Pharma virus
Talphera, Inc. (formerly AcelRx Pharmaceuticals) is a pharmaceutical company focused on developing and commercializing therapeutics for use in healthcare settings. This chart reflects the profitability of its antiviral and other segments. Business refocusing and new developments influence its contribution to overall performance, demonstrating the evolution and adaptation within the pharmaceutical industry.
Overall market profit
Talphera, Inc. is a specialty pharmaceutical company developing and commercializing products to treat diseases with high unmet needs. Its success depends on regulatory approvals and a strong go-to-market strategy, making it less dependent on the general economic cycles shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Talphera Inc.
Talphera, Inc. (formerly AcelRx Pharmaceuticals) focuses on developing and commercializing medications for use in healthcare settings under physician supervision. This chart reflects analysts' expectations for future revenue, which depend on the adoption of its products by hospitals and clinics. It demonstrates the market's confidence in the potential of niche hospital medications.
%20profit%20of%20the%20company%20Talphera%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Talphera-Inc.&v=1772540176259 "Graph of future (projected) profit of the company Talphera Inc.")
Future (predicted) profit of companies in the market segment - Pharma virus
Talphera, Inc. is a specialty pharmaceutical company developing and commercializing products to treat diseases with significant unmet needs. This chart shows profitability forecasts for the antiviral pharmaceutical segment. It reflects expectations for niche drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-virus&v=1772540176302 "Graph of future (predicted) profits of companies in a market segment - Pharma virus")
Future (predicted) profit of the market as a whole
Talphera develops drugs for the treatment of viral diseases and oncology. Like many biotech companies, the overall market revenue forecast is important for them in terms of the investment climate. Economic growth expectations, reflected in the graph, facilitate the raising of capital for costly clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772540176339 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Talphera Inc.
Talphera, Inc. is a pharmaceutical company specializing in the development of drugs for the treatment of viral and other diseases. P/S will become an important metric after the commercialization of its products, reflecting their market potential and investor valuation.
P/S market segment - Pharma virus
Talphera, Inc. (formerly AcelRx Pharmaceuticals) specializes in the development and commercialization of acute pain treatments, specifically sublingual tablets. This chart shows how the market assesses the commercial potential of their approved products and their ability to compete with traditional pain medications, such as opioids.
P/S of the market as a whole
Talphera is a pharmaceutical company specializing in the development of drugs to treat viral and bacterial infections. Revenue is dependent on the success of clinical trials and commercialization. This revenue estimate chart provides a backdrop for how highly the market values the potential of companies fighting infectious diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Talphera Inc.
Talphera, Inc., formerly AcelRx Pharmaceuticals, is focused on developing and commercializing products for hospital-based treatments requiring rapid response. This schedule reflects investor expectations for future sales of its specialized medications intended for use in controlled clinical settings.
%20P%2FS%20Talphera%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Talphera-Inc.&v=1772540176617 "The graph of the company's future (projected) P/S Talphera Inc.")
Future (projected) P/S of the market segment - Pharma virus
Talphera, Inc. is a specialty pharmaceutical company developing and commercializing products for the treatment of lung diseases and other serious conditions. This chart shows how the market estimates future sales of its drugs. It compares it to other companies in the antiviral pharmaceutical sector, reflecting its niche specialization and development pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20virus&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-virus&v=1772540176625 "Future (projected) P/S market segment graph - Pharma virus")
Future (projected) P/S of the market as a whole
Talphera is a pharmaceutical company specializing in the development of acute care medications, specifically a nasal spray for the treatment of seizures. This chart shows investor consensus revenue forecasts, and TLPH demonstrates how companies solving acute medical problems can find their niche and achieve commercial success.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772540176639 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Talphera Inc.
Talphera, Inc. is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases. Its revenue, shown in this chart, is generated from sales of its approved product and may also include revenue from licensing agreements. Growth depends on the successful marketing of the drug.
Sales of companies in the market segment - Pharma virus
Talphera is a pharmaceutical company focused on developing drugs to treat life-threatening conditions. At this stage, its revenue, if any, may be derived from partnerships. This chart allows investors to assess the financial flows supporting the company's path to commercialization.
Overall market sales
Talphera, Inc., formerly AcelRx Pharmaceuticals, focuses on developing medications for inpatient use. Demand for such products is driven by hospital needs, not by general economic cycles. This timeline is irrelevant to Talphera, whose success depends on the effectiveness of its medications and their integration into clinical practice.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Talphera Inc.
Talphera (formerly AcelRx Pharmaceuticals) focuses on the development and commercialization of medications for hospital use. Its revenue forecast depends on sales of its already approved products and the success of new developments. This chart shows analysts' estimates of demand for its specialty pharmaceuticals.
%20sales%20of%20the%20company%20Talphera%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Talphera-Inc.&v=1772540176793 "Schedule of future (projected) sales of the company Talphera Inc.")
Future (projected) sales of companies in the market segment - Pharma virus
Talphera, Inc. (formerly AcelRx Pharmaceuticals) specializes in developing medications for the treatment of acute conditions. This chart shows projected revenue for the entire antiviral and therapeutic segment. It helps assess demand for innovative dosage forms that provide rapid and effective action, a key feature of Talphera's products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-virus&v=1772540176801 "Schedule of future (projected) sales of companies in the market segment - Pharma virus")
Future (projected) sales of the market as a whole
Talphera is a pharmaceutical company developing drugs to treat viral and other diseases. Its future depends on the success of clinical trials and regulatory approval. This graph of overall market expectations reflects the investment climate. A positive environment facilitates raising the capital needed to finance expensive and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772540176854 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Talphera Inc.
Talphera, Inc. is a pharmaceutical company specializing in the development of drugs for the treatment of viral and other diseases. This chart depicts its path to commercialization. Future profitability depends on regulatory approval of its drugs and their successful launch.
Market segment marginality - Pharma virus
Talphera, Inc. is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare diseases, particularly those associated with viruses. This chart reflects the average profit margin in the pharmaceutical industry. It provides context for assessing the potential profitability of the company's niche products if they are successfully launched.
Market marginality as a whole
Talphera, Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of viral and immune system diseases. This gross margin chart is irrelevant to the company's valuation, as its value depends on scientific breakthroughs and successful regulatory clearance.
Employees in the company, segment and market as a whole
Number of employees in the company Talphera Inc.
Talphera (formerly AcelRx) is a pharmaceutical company focused on emergency medicine. Following its restructuring, its team likely became leaner and more focused on advancing its core product. This graph may reflect a shift to a leaner operating model.
Share of the company's employees Talphera Inc. within the market segment - Pharma virus
Talphera, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases. This chart highlights its scientific focus. It reflects the proportion of clinicians and researchers working with Talphera to create innovative therapeutic solutions for patients with limited treatment options.
Number of employees in the market segment - Pharma virus
Talphera, Inc. is a biopharmaceutical company specializing in the development of drugs for the treatment of viral diseases and oncology. This chart shows employment in the viral pharmaceuticals sector. The growing number of scientists in this field reflects the ongoing need for new antiviral agents and the search for innovative approaches to cancer treatment.
Number of employees in the market as a whole
Talphera, Inc. is a biopharmaceutical company specializing in the development of drugs to treat viral diseases and other serious conditions. Pandemics have demonstrated the importance of antiviral research. This chart shows overall employment, and investments in this area are strategically important for national security and public health.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Talphera Inc. (TLPH)
Talphera, Inc. is a pharmaceutical company, and its valuation is based on future sales. This chart shows the market's perception of its R&D portfolio. High market capitalization per employee is the norm for such companies, as investors value the potential of intellectual property rather than current revenue.
%20of%20the%20company%20Talphera%20Inc.%20(TLPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Talphera-Inc.-TLPH&v=1772540177212 "Chart of market capitalization per employee (in thousands of dollars) of the company Talphera Inc. (TLPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma virus
Talphera is a pharmaceutical company developing drugs to treat infectious diseases. Its market value per employee reflects investors' valuation of its clinical pipeline. This high figure, compared to other sectors, indicates a significant potential market for its products if approved.
%20by%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-virus&v=1772540177252 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma virus")
Market capitalization per employee (in thousands of dollars) for the overall market
Talphera is a pharmaceutical company specializing in the development and commercialization of drugs for specific patient needs. This chart reflects how the market evaluates the team's ability to identify niche markets and bring needed drugs to them, effectively managing the process from development to sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772540177315 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Talphera Inc. (TLPH)
Talphera (formerly AcelRx) is a pharmaceutical company shifting its focus from its acute pain treatment products to new developments (such as Niyad). This chart reflects this transformation: how much revenue (or losses) from older products offsets the R&D staff working on the new portfolio, and the overall team effectiveness.
%20Chart%20Talphera%20Inc.%20(TLPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Talphera-Inc.-TLPH&v=1772540177386 "Company Profit Per Employee (in thousands of dollars) Chart Talphera Inc. (TLPH)")
Profit per employee (in thousands of dollars) in the market segment - Pharma virus
Talphera, Inc. is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare and serious diseases. This chart reflects the potential value of their portfolio. It shows how much profit a single successful drug in a niche market could generate, which is a measure of the effectiveness of their orphan disease strategy.
%20in%20the%20market%20segment%20-%20Pharma%20virus&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-virus&v=1772540177457 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma virus")
Profit per employee (in thousands of dollars) for the market as a whole
Talphera, Inc. (formerly AcelRx) is a pharmaceutical company focused on emergency and critical care medications (e.g., Dsuvia). This metric reflects how successfully the company is commercializing its approved but niche products. It shows the balance between the costs of a small staff (sales, R&D) and sales revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772540177553 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Talphera Inc. (TLPH)
Talphera, Inc. is a pharmaceutical company developing drugs for rare diseases. At the pre-commercialization stage, this chart does not reflect operational efficiency. It represents potential. A successful product launch will lead to a sharp increase in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Talphera-Inc.-TLPH&v=1772540177605 "Sales chart per company employee Talphera Inc. (TLPH)")
Sales per employee in the market segment - Pharma virus
Talphera (TLPH) is a biopharmaceutical company specializing in the development of drugs for the treatment of viral and oncological diseases using its delivery technology. This chart shows the average revenue per employee in the pharmaceutical segment. For Talphera, which is in the R&D stage, comparing it to this benchmark (zero) highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
Talphera (TLPH) is a biotech company (formerly AcelRx) focused on emergency medicine. The company has approved products. This metric measures how successfully their commercial team sells these highly specialized drugs to hospitals and the military. Growth indicates a successful sales strategy.
Short shares by company, segment and market as a whole
Shares shorted by company Talphera Inc. (TLPH)
Talphera (formerly AcelRx) is a pharmaceutical company focused on emergency and hospital-use medications. Their key product (Dsuvia, a sublingual opioid) has seen very weak sales. This chart shows the odds on commercial failure. "Bears" believe the company will be unable to bring its niche drugs to market and will run out of cash.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Talphera-Inc.-TLPH&v=1772540177898 "Short Shares Chart for the Company Talphera Inc. (TLPH)")
Shares shorted by market segment - Pharma virus
Talphera (TLPH) is a biotech company attempting to reformulate old, well-known drugs (such as flu medications) into new forms (such as a spray). This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that this model of "improving" generics won't pay off. Investors doubt that insurers will pay a premium for "convenience" when cheaper pills are available.
Shares shorted by the overall market
Talphera (TLPH) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Talphera Inc. (TLPH)
Talphera is a biotech company developing treatments for viral and other diseases. It's a risky R&D business. This chart is a "cardiogram" of hope. It shows how the "temperature" of investor interest can suddenly "heat up" to a peak on any positive news about clinical trials, and then "cool down" again.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Talphera-Inc.-TLPH&v=1772540178000 "RSI 14 indicator chart for the company's stock Talphera Inc. (TLPH)")
RSI 14 Market Segment - Pharma virus
Talphera (formerly Sol-Gel) is a biopharmaceutical company specializing in dermatology. They use their microencapsulation technology to create treatments for acne and rosacea. This chart reflects the overall sentiment in the biotech sector, helping to gauge how the market views this speculative industry.
RSI 14 for the overall market
Talphera (TLPH) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TLPH (Talphera Inc.)
Talphera (TLPH) is a pharmaceutical company focused on developing drugs to treat viral and bacterial infections. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of its clinical pipeline and the likelihood of new drug approvals.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TLPH-Talphera-Inc.&v=1772540178114 "A chart showing analyst consensus forecasts for the expected stock price. TLPH (Talphera Inc.)")
The difference between the consensus estimate and the actual stock price TLPH (Talphera Inc.)
Talphera is a biopharmaceutical company specializing in developing drugs to treat viral and other diseases. This chart shows the difference between the market valuation and the consensus estimate. For an R&D company, this gap reflects analysts' confidence in their scientific pipeline and the likelihood of success in clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TLPH-Talphera-Inc.&v=1772540178137 "A chart showing the difference between the consensus forecast and the actual stock price. TLPH (Talphera Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma virus
Talphera (formerly AcelRx) is a specialty pharmaceutical company focused on sedation medications for patients during medical procedures. This chart reflects analysts' overall expectations for the pharmaceutical sector. It shows whether experts believe the hospital market for sedation medications will grow.
Analysts' consensus forecast for the overall market share price
Talphera (formerly AcelRx) is a biotech company that (after a shift in focus) now develops drugs to treat viral and bacterial infections. This chart shows the overall market "risk appetite." For Talphera, a company in a "reset," overall market optimism (risk appetite) is critical to raising the capital needed to fund its new strategy.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Talphera Inc.
Talphera (formerly AcelRx) is a pharmaceutical company that has rebooted itself. Their signature approach is sublingual drug delivery. Having failed with opioids, they are now using this technology to treat viral infections. This chart is a summary indicator of their second chance. It reflects their (very risky) R&D pipeline and their struggle to keep up with the money.
AKIMA Market Segment Index - Pharma virus
Talphera (TLPH) is a biopharmaceutical company focused on developing treatments for viral and other diseases with unmet needs. This chart shows the segment average. It helps investors assess how the risks and potential of Talphera's developments compare to the average for the pharmaceutical sector tackling viral threats.
The AKIM Index for the overall market
Talphera (formerly AcelRx) is a specialty pharmaceutical company focused on products for use in healthcare settings (anticoagulants). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is restructuring its portfolio, compares to overall economic trends.
